Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis

1

The study analyzed 75 patients undergoing alloHCT, categorizing them by COVID-19 severity to assess its impact on transplant outcomes.
2

Patients with mild COVID-19 had significantly better overall survival (90.9%) compared to those with moderate (66.7%) and severe/critical (51.1%) cases.
3

A high Karnofsky Index (90-100) was a significant predictor of better disease-free survival compared to a lower index (<90) in alloHCT patients.
4

The study found no significant association between COVID-19 severity and the incidence of Graft-versus-Host Disease (GvHD) in patients.
5

The results emphasize the importance of functional status assessment and preventive measures like vaccination in optimizing alloHCT outcomes.

Bone Marrow Transplantation

by Osama Ahmad, Nicolaus Kröger, Eva Wagner-Drouet, David Nachbaur, Normann Steiner, Daniel Teschner, Sabrina Kraus, Gesine Bug, Salem Ajib, Johannes Schetelig, Wolfgang Andreas Bethge, Thomas Schroeder, Judith Schaffrath, Lutz Peter Müller, Mareike Verbeek, Edgar Jost, Hatice Soysal, Johanna Tischer, Georg-Nikolaus Franke, Stefan Klein, Udo Holtick, Knut Wendelin, Claudia Lengerke, Martin Bornhäuser, Jan Frederic Weller, Maximilian Christopeit
March 12, 2025

1